Business Wire

CORFLOW-THERAPEUTICS-AG

Del

CorFlow Presents Fundamental New Insights into the Coronary Microcirculation at ACC

CorFlow Therapeutics AG (www.corflow-therapeutics.ch ) today announced that the company will present fundamental new insights into the coronary microcirculation during the annual meeting of the American College of Cardiology (ACC) in Orlando, FL, March 10-12, 2018.

CorFlow has since its foundation in June 2016 worked to document that the Controlled Flow Infusion (CoFITM ) technology is able to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time. Microvascular obstruction (MVO) affects more than half of the acute heart attack patients and is an independent predictor for complications including heart failure which constitutes a high cost burden for the world-wide health care system. To address this large unmet medical need in interventional cardiology, CorFlow has developed an in-vivo model which reproducibly creates MVO in an occlusion-reperfusion model with very low complication rates. Using this in-vivo model, the CoFITM  technology was used to measure real-time dynamic microvascular resistance (dMVR) in the coronary circulation and these dMVR values were correlated to post-procedure contrast enhanced magnetic resonance imaging (MRI) and histology. A correlation between the procedural CoFITM  dMVR values and post-procedural MRI will enable treatment of MVO before the patients leave the cathlab and potentially reduce the complication rates for severe heart attack patients.

In a comment, Dr. Renu Virmani, an internationally renowned cardiovascular pathologist and co-author of the histology poster, stated: "These findings suggest that the fundamental effects of a human heart attack have to be reconsidered. Our findings show that MVO in acute heart attacks can be created without the presence of thrombi. The results furthermore show that minute reductions in coronary volume flow causes an exponential collapse of the coronary microcirculation and that epicardial revascularization alone is not sufficient to open the collapsed coronary microcirculation. If these findings hold true in our upcoming investigations, we will have to fundamentally rethink the comprehensive treatment of an acute heart attack with attention to the microvasculature as well as the major epicardial vessels."

Jon H. Hoem, CorFlow's CEO and co-Founder, commented: "We are very pleased that our in-vivo results have been accepted for publication during the important ACC conference and look forward to discuss these results with cardiologists attending the conference."

The data from the CorFlow non-clinical trials will be used in the upcoming submissions for the CorFlow MOCA I (M VO  with C oFI™ System A ssessment I) First-in-Man clinical trial.

Contact:

CorFlow Therapeutics AG
Jon H. Hoem, +41 79 606 2 902
jhoem@corflow-therapeutics.ch

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com